GSK, a unique company in Belgium
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

We have 3 global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.

Our goal is to be one of the world's most innovative, best performing and trusted healthcare companies.
Our strategy
Bring quality, needed healthcare products to as many people as possible, with our scientific and technical know-how and talented people.

Our values and expectations
- Patient focus
- Transparency
- Respect
- Integrity
- Courage
- Accountability
- Development
- Teamwork
What we do

We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our 3 global businesses, scientific and technical knowhow and talented people.

Mvelo
Patient

Please report adverse events to the Belgian Centre for Pharmacovigilance for medicines for Human use (BCPH) of the Federal Agency for Medicines and Health Products (FAMHP) on the following address: adversedrugreactions@afmps.be or via the ‘yellow card’ available on the website http://www.fagg-afmps.be or to GlaxoSmithKline Pharmaceuticals s.a./n.v. at the number 010/ 85 85 00.
Vaccines

Our Vaccines business has a broad portfolio and innovative pipeline of vaccines to help protect people throughout life. These vaccines help to protect against many infectious diseases such as meningococcal, pneumococcal or rotavirus infections, as well as polio, flu, hepatitis, whooping cough or shingles infections.

>40 vaccines for children, adolescents, adults and travelers.

A tradition of innovation

GSK pioneers innovative vaccines worldwide.

Date of commercialisation in Belgium

and in the near future...

Shingrix
Pharmaceuticals

Our Pharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in respiratory and HIV. Our R&D approach focuses on science related to the immune system, use of genetics and advanced technologies.

Respiratory

>45 years
of research and development for innovative respiratory drugs.

1969 Ventolin
1972 Beconase
1973 Becotide
1990 Flixonase
1993 Flixtide
1999 Seretide
2018 Trelegy Ellipta
2016 Nucala
2015 Anoro Ellipta & Incruse Ellipta
2014 Relvar Ellipta
2008 Avamys

HIV

A unique company fully dedicated to the fight against HIV, specialised in treatment with currently

>10 specific medicines
for people living with the virus.
Consumer Healthcare

Our Consumer Healthcare business develops and markets an innovative portfolio of consumer preferred and expert recommended brands in the **Oral health**, **Pain relief**, **Respiratory**, and **Skin health** categories.

160 years of experience

Parodontax

Depiction of Hydroxyapatite like crystals which *NovaMin* helps to form.
How we do it

Everyone at GSK is focused on 3 priorities:

- Innovation
- Performance
- Trust
Innovation

We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.

€4.3bn
R&D investment in 2017

3
major launches in 2017 – Shingrix, a vaccine for shingles, Trelegy Ellipta for COPD and Juluca for HIV

27
immunomodulatory new molecular entities in the pipeline for a range of diseases

11,000
people working in R&D around the world

In 2018 GSK announced a new collaboration with 23andMe, to develop innovative new medicines and potential cures, using human genetics as the basis for discovery.

Rodrigo
Cell Transduction Scientist
Our long-term priorities

Performance

We aim to achieve industry-leading growth by investing effectively in our business, developing our people and delivering flawlessly.

€33.4bn
Total turnover in 2017

No.1
dolutegravir is the most prescribed core agent for HIV treatments worldwide

>€1bn
Sensodyne sales - world’s number one dentist recommended toothpaste for sensitive teeth

>100m
Ellipta inhalers produced to treat asthma and COPD

Around 40% of the world’s children are protected with at least one GSK vaccine.

2 millions doses of our vaccines are delivered to 160 countries per day.
Our long-term priorities

Trust

We are a responsible company and commit to use our science and technology to address health needs, make our products affordable and available and to be a modern employer.

119,000 of our people and their families in 93 countries have access to healthcare with our Partnership for Prevention programme

1st candidate vaccine showing efficacy against malaria and 1st single dose medicine to treat relapsing malaria

1st in class medicines in the pipeline and a much needed candidate vaccine to help fight tuberculosis

84% of employees are proud to work for GSK

Our approach to global health focuses our science on three of the biggest health challenges affecting children and young people in the developing world – HIV, TB and malaria.

Each year 6 million children under the age of five die, most from preventable causes in developing countries.

Eva
Scientist
Our vaccine heritage can be traced back to Piet De Somer (who became the first rector of the KUL). Christian de Duve (future Nobel price winner) was also working as a scientific researcher. These two Belgians were responsible for the first research involving penicillin and antiviral vaccines in 1945.
GSK is one of the few pharmaceutical companies that has integrated all operations: from research to development, to production and finally commercialisation of vaccines:

- **R&D** (research and clinical development)
- Manufacturing and **packaging** (primary and secondary)
- **Distribution** in Belgium and **export** all around the world

But also the **commercialisation of medicines** against respiratory disease and HIV (the virus responsible for AIDS), as well as many consumer healthcare products.

**Belgium: the heart of GSK Vaccines**

3 **major vaccine sites** of GSK in Belgium (in Wavre, Rixensart and Gembloux), including the **global headquarters** from the **vaccines division** of the group.

We represent the **largest industrial network** for vaccines worldwide.
Rixensart

- Founded in 1958, this was the foundational vaccines site in Belgium. Many of our vaccines were discovered and produced here.

- The site is unique and is home to the largest vaccines R&D unit. Our other R&D sites are in Italy and the USA.

- There are specific laboratories dedicated to research and development of vaccines as well as vaccine manufacturing.

- Our R&D team brings together a vast and unique international expertise across the fields of adjuvants as well as viral and bacterial infections.

The names of our vaccines developed in Belgium always end with -RIX.
Wavre

- Inaugurated in 1995, this site is the largest vaccines manufacturing site in the world with a total surface of 550,000 m². It is equipped with a large manufacturing infrastructure (producing antigens, formulation, filling, packaging, and infrastructure for quality assurance and control).

- The vast majority of GSK Vaccines distributed worldwide are produced in Wavre.

Gembloux

- Created in 1997, this site is dedicated to upscaling vaccine manufacturing techniques before their implementation in our Belgian and international manufacturing centers.

- This site is also important for the storage of our vaccines (commissioned since 2010).
GSK in Belgium, in numbers

14 candidate vaccines currently in development, representing the largest pipeline compared to other vaccine producers*

65 years of innovation in vaccines, with currently ~2,000 researchers working in R&D.

>90% of the vaccines in our pipeline were developed through Belgian and international partnerships. In 2018, we had 13 scientific collaborations with Belgian academic institutions.

Investments are key to anticipate the future in a complex domain

~1 billion € invested in R&D as from Belgium in 2017. On top of that, 3 billion € were invested in Belgian infrastructure the last 10 years.

The launch of a new vaccine is a long process and requires massive investments in R&D (including clinical trials) as well as in development and building state-of-the-art facilities.

Our investments in R&D have continuously increased over the last decade.

*www.accesstovaccinesindex.org
99% of our vaccines are exported to >160 countries of which at least 70% are developing countries with low and middle incomes.

>2 million doses of vaccines are produced every day

800 million doses of vaccines distributed in 2017, or 25 doses/second
In the last 10 years, GSK has created more than 3,000 jobs, which corresponds to almost 1 job created/day.

In 2017, GSK hired about 1,000 employees.

>9,000 employees in Belgium without counting about 16,000 indirect jobs created. GSK is by far the largest pharmaceutical company in Belgium.

A Top 10 company in Belgium

>80 nationalities across our workforce in Belgium.

45% women and 55% men

25% operators
35% administrative & technical functions
40% managers

In 2017, close to 2,000 of our GSK employees dedicated their time to 137 charity projects.

Future Leaders Programme*
Every year through this programme young talent has the opportunity to experience different parts of our business.

Consistently recognized as an attractive employer over several years.

>9,000 employees in Belgium

9,000 employees in Belgium without counting about 16,000 indirect jobs created. GSK is by far the largest pharmaceutical company in Belgium.

A Top 10 company in Belgium

>80 nationalities across our workforce in Belgium.

45% women and 55% men

25% operators
35% administrative & technical functions
40% managers

In 2017, close to 2,000 of our GSK employees dedicated their time to 137 charity projects.

Future Leaders Programme*
Every year through this programme young talent has the opportunity to experience different parts of our business.

Consistently recognized as an attractive employer over several years.
The impact of our vaccines on public health

Next to clear water, nothing has a bigger impact than vaccination in its ability to save lives*. The WHO estimates 2-3 million of deaths are prevented each year thanks to vaccination**.

>40 vaccines on the market which help protect against infectious diseases at all stages of life - from infants to elderly, as well as pregnant women and travelers.

The majority of Belgians will receive at least 1 GSK vaccine during their lifetime.

GSK has a vaccine for each infectious disease mentioned in the Belgian vaccination calendar.

40% of children worldwide are protected with at least one GSK vaccine.

**www.who.int/mediacentre/factsheets/fs378/fr/
Debora, Elomvi, Imaculé, Koké, Kodjo, Essenam
Patients
The impact of our vaccines on global health

We focus our science on three of the biggest health challenges affecting children and young people in the developing world - HIV, TB and malaria. After more than 30 years of research by our scientists in Belgium in collaboration with international partners, the first vaccine, Mosquirix, indicated for malaria prevention is finally available for children living in Sub-Saharan Africa. GSK will distribute this vaccine at access pricing and has committed to donate the first 10 million doses to WHO.

Making our vaccines available for as many people as possible

In order to increase access of our vaccines and medicines to patients, independently of their financial situation, we collaborate with partners (UNICEF, GAVI…) to set up different help programmes. GSK is the main vaccine supplier to these organisations.

GSK has ranked top of the Access to Medicines Index for the past ten years as the company contributing most to improve the access of medicines throughout the world.

7/10 of our vaccines are distributed to developing countries where we apply a differentiated pricing policy.

400,000 people die every year from malaria, mostly children and pregnant women... that’s one child every 2 minutes.
Producing a vaccine: a long and complex process

Vaccines are complex biological products where the manufacturing is based on living organisms. The reproducibility of the manufacturing process is technically complex.

The different steps of vaccine manufacturing

**R&D**
10-30 years

- Receipt of raw materials
  - 2 weeks

**Cold chain** ± 18-26 months

- Packaging, batch release and transport
  - 6-18 weeks
Manufacturing of the vaccine antigens
10-12 months

Quality checks all through the process

70% of the manufacturing process is dedicated to quality control.

>100 quality controls are needed for producing and before releasing a vaccine batch.

Formulation, filling and quality control
6-10 months

Quality checks:
- from the producer
- from the exporting country
- from the importing country
GSK, a unique company in Belgium!

Unique…

… historical R&D site in Rixensart, explaining why most of our vaccines end with “-RIX”.

… broadest portfolio of vaccines that help protect people throughout life against infectious disease.

… not only do we have the largest “pipeline” of vaccines, but we are also the largest vaccine manufacturer worldwide.

… GSK has massively invested in R&D and infrastructure during the last decade.

… Wavre is the largest vaccine production facility in the world.

… our pharmaceutical business has integrated all biopharmaceutical activities in one location (from R&D to commercialisation).

… >3,000 direct jobs created in 10 years.

For more information, please consult our website http://be.gsk.com

Elisabeth Van Damme
Director External Communications
✉ elisabeth.e.vandamme@gsk.com | ☎ +32 (0)478 27 26 41

Brand names appearing in italics in this document are trade marked either owned by and/or licensed to GlaxoSmithKline or associated companies.